Currently, there are 128.06M common shares owned by the public and among those 126.84M shares have been available to trade.
The company’s stock has a 5-day price change of 0.00% and 17.31% over the past three months. NEO shares are trading 8.47% year to date (YTD), with the 12-month market performance down to -15.34% lower. It has a 12-month low price of $12.77 and touched a high of $20.94 over the same period. NEO has an average intraday trading volume of 783.84K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.13%, 8.61%, and 13.65% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Neogenomics Inc (NASDAQ: NEO) shares accounts for 97.50% of the company’s 128.06M shares outstanding.
It has a market capitalization of $2.25B and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$0.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.82% over the week and 3.91% over the month.
Earnings per share for the fiscal year are expected to increase by 181.67%, and 99.58% over the next financial year.
Looking at the support for the NEO, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on December 10, 2024, with the firm’s price target at $22. Craig Hallum coverage for the Neogenomics Inc (NEO) stock in a research note released on May 01, 2024 offered a Buy rating with a price target of $26. BTIG Research was of a view on December 29, 2023 that the stock is Buy, while Stephens gave the stock Overweight rating on August 21, 2023, issuing a price target of $18. Raymond James on their part issued Mkt Perform rating on May 16, 2023.
